TANDEM DIABETES CARE INC (TNDM) Fundamental Analysis & Valuation

NASDAQ:TNDM • US8753722037

Current stock price

18.61 USD
-0.2 (-1.06%)
At close:
18.61 USD
0 (0%)
After Hours:

This TNDM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TNDM Profitability Analysis

1.1 Basic Checks

  • In the past year TNDM has reported negative net income.
  • In the past year TNDM has reported a negative cash flow from operations.
  • In the past 5 years TNDM reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: TNDM reported negative operating cash flow in multiple years.
TNDM Yearly Net Income VS EBIT VS OCF VS FCFTNDM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • With a Return On Assets value of -23.23%, TNDM perfoms like the industry average, outperforming 47.34% of the companies in the same industry.
  • With a Return On Equity value of -131.93%, TNDM is not doing good in the industry: 68.09% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -23.23%
ROE -131.93%
ROIC N/A
ROA(3y)-18.84%
ROA(5y)-12.76%
ROE(3y)-79.8%
ROE(5y)-51.46%
ROIC(3y)N/A
ROIC(5y)N/A
TNDM Yearly ROA, ROE, ROICTNDM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K

1.3 Margins

  • The Gross Margin of TNDM (53.81%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of TNDM has remained more or less at the same level.
  • TNDM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.44%
GM growth 5Y0.6%
TNDM Yearly Profit, Operating, Gross MarginsTNDM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TNDM Health Analysis

2.1 Basic Checks

  • TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TNDM has more shares outstanding
  • TNDM has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TNDM has been reduced compared to a year ago.
TNDM Yearly Shares OutstandingTNDM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
TNDM Yearly Total Debt VS Total AssetsTNDM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 0.44, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of TNDM (0.44) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 2.03 is on the high side and indicates that TNDM has dependencies on debt financing.
  • TNDM has a worse Debt to Equity ratio (2.03) than 81.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 0.44
ROIC/WACCN/A
WACC9.59%
TNDM Yearly LT Debt VS Equity VS FCFTNDM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • TNDM has a Current Ratio of 2.55. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
  • TNDM's Current ratio of 2.55 is in line compared to the rest of the industry. TNDM outperforms 50.53% of its industry peers.
  • TNDM has a Quick Ratio of 2.02. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TNDM (2.02) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.55
Quick Ratio 2.02
TNDM Yearly Current Assets VS Current LiabilitesTNDM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TNDM Growth Analysis

3.1 Past

  • TNDM shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.97%.
  • TNDM shows a small growth in Revenue. In the last year, the Revenue has grown by 7.93%.
  • TNDM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.26% yearly.
EPS 1Y (TTM)-0.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)7.93%
Revenue growth 3Y8.19%
Revenue growth 5Y15.26%
Sales Q2Q%2.74%

3.2 Future

  • Based on estimates for the next years, TNDM will show a very strong growth in Earnings Per Share. The EPS will grow by 25.69% on average per year.
  • Based on estimates for the next years, TNDM will show a quite strong growth in Revenue. The Revenue will grow by 9.86% on average per year.
EPS Next Y48.96%
EPS Next 2Y40.59%
EPS Next 3Y36.66%
EPS Next 5Y25.69%
Revenue Next Year7.35%
Revenue Next 2Y9.71%
Revenue Next 3Y11.1%
Revenue Next 5Y9.86%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TNDM Yearly Revenue VS EstimatesTNDM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
TNDM Yearly EPS VS EstimatesTNDM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. TNDM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TNDM. In the last year negative earnings were reported.
  • Also next year TNDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNDM Price Earnings VS Forward Price EarningsTNDM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNDM Per share dataTNDM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • TNDM's earnings are expected to grow with 36.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.59%
EPS Next 3Y36.66%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TNDM Dividend Analysis

5.1 Amount

  • TNDM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TNDM Fundamentals: All Metrics, Ratios and Statistics

TANDEM DIABETES CARE INC

NASDAQ:TNDM (4/2/2026, 4:30:01 PM)

After market: 18.61 0 (0%)

18.61

-0.2 (-1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-19
Earnings (Next)04-28
Inst Owners112.72%
Inst Owner Change-1.63%
Ins Owners0.74%
Ins Owner Change6.82%
Market Cap1.27B
Revenue(TTM)1.01B
Net Income(TTM)-204.71M
Analysts74
Price Target31.62 (69.91%)
Short Float %15.55%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.63%
Min EPS beat(2)3.18%
Max EPS beat(2)88.09%
EPS beat(4)2
Avg EPS beat(4)16.73%
Min EPS beat(4)-18.66%
Max EPS beat(4)88.09%
EPS beat(8)6
Avg EPS beat(8)27.33%
EPS beat(12)6
Avg EPS beat(12)-5.15%
EPS beat(16)6
Avg EPS beat(16)-122.52%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)2.76%
Max Revenue beat(2)3.12%
Revenue beat(4)3
Avg Revenue beat(4)2.29%
Min Revenue beat(4)-1.1%
Max Revenue beat(4)4.37%
Revenue beat(8)7
Avg Revenue beat(8)5.14%
Revenue beat(12)7
Avg Revenue beat(12)2.23%
Revenue beat(16)8
Avg Revenue beat(16)1.18%
PT rev (1m)6.4%
PT rev (3m)34.25%
EPS NQ rev (1m)-5.74%
EPS NQ rev (3m)-9.11%
EPS NY rev (1m)23.42%
EPS NY rev (3m)22.51%
Revenue NQ rev (1m)-1.08%
Revenue NQ rev (3m)-3.56%
Revenue NY rev (1m)-2.66%
Revenue NY rev (3m)-2.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.25
P/FCF N/A
P/OCF N/A
P/B 8.2
P/tB 8.86
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS14.85
BVpS2.27
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.23%
ROE -131.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.81%
FCFM N/A
ROA(3y)-18.84%
ROA(5y)-12.76%
ROE(3y)-79.8%
ROE(5y)-51.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.44%
GM growth 5Y0.6%
F-Score4
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.92%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.55
Quick Ratio 2.02
Altman-Z 0.44
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)278.84%
Cap/Depr(5y)261.5%
Cap/Sales(3y)5.28%
Cap/Sales(5y)4.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y48.96%
EPS Next 2Y40.59%
EPS Next 3Y36.66%
EPS Next 5Y25.69%
Revenue 1Y (TTM)7.93%
Revenue growth 3Y8.19%
Revenue growth 5Y15.26%
Sales Q2Q%2.74%
Revenue Next Year7.35%
Revenue Next 2Y9.71%
Revenue Next 3Y11.1%
Revenue Next 5Y9.86%
EBIT growth 1Y21.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.87%
EBIT Next 3Y51.09%
EBIT Next 5Y33.87%
FCF growth 1Y28.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.13%
OCF growth 3YN/A
OCF growth 5YN/A

TANDEM DIABETES CARE INC / TNDM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TANDEM DIABETES CARE INC (TNDM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TNDM.


What is the valuation status of TANDEM DIABETES CARE INC (TNDM) stock?

ChartMill assigns a valuation rating of 1 / 10 to TANDEM DIABETES CARE INC (TNDM). This can be considered as Overvalued.


What is the profitability of TNDM stock?

TANDEM DIABETES CARE INC (TNDM) has a profitability rating of 1 / 10.


Can you provide the financial health for TNDM stock?

The financial health rating of TANDEM DIABETES CARE INC (TNDM) is 3 / 10.